Companies

Laurus Labs gets two observations from USFDA for its Unit 2

Our Bureau Hyderabad | Updated on November 08, 2019 Published on November 08, 2019

Laurus Labs Ltd has completed the US Food and Drug Administration (USFDA) inspection of its Unit – 2 (FDF&API integrated facility), located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh with two observations.

“The observations are in procedural in nature,’’ the Hyderabad-based Laurus said in a release.

This was a product pre-approval audit by USFDA, and no data integrity issues were observed in the inspection. The inspection was carried out from November 4-8, the company said.

Laurus Labs scrip lost 0.78 per cent to end at ₹366.90 on the BSE on Friday.

Published on November 08, 2019
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.